enterprise guide software version 7.1 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
enterprise guide software version 7.1
Enterprise Guide Software Version 7.1, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enterprise+guide+software+version+7%2E1/enterprise+guide+7+1/pm40635490-58-8-13
Average 90 stars, based on 1 article reviews
Enterprise Guide Software Version 7.1, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enterprise+guide+software+version+7%2E1/enterprise+guide+7+1/pm40635490-58-8-13
Average 90 stars, based on 1 article reviews
enterprise guide software version 7.1 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Alternative Plant Protection Strategies Using Bacteria and Thyme to Improve Strawberry (cv. Elsanta) Yield and Quality. Article Snippet: All measurements and analyses were performed using the Article Title: Intravenous Sodium Ferric Gluconate Complex for Hospitalized Pediatric Patients with Iron Deficiency Anemia. Article Snippet: All statistical analyses for this project were completed using Article Title: Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States. Article Snippet: All results were descriptively assessed using SAS Article Title: Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP. Article Snippet: Real-world clinical outcomes of asciminib, an ABL/BCR::ABL1 tyrosine kinase inhibitor (TKI), were evaluated in US clinical practice.. In patients with chronic myeloid leukemia in chronic phase treated with asciminib after ≥2 prior TKIs, almost 80% of patients remained on asciminib and 50% achieved or maintained a major molecular response by 24 weeks, suggesting that asciminib was well-tolerated and effective.. Background: Tyrosine kinase inhibitors (TKIs) are the mainstay treatment for chronic myeloid leukemia in chronic phase (CML-CP). Article Title: Clinical impacts of COVID-19 on severe exacerbation and mortality in interstitial lung disease: prognosis 30 days after infection. Article Snippet: All statistical analyses were carried out using SAS Article Title: Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer Article Snippet: All analyses were conducted using SAS Article Title: New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: A nationwide population-based cohort study. Article Snippet: Aim: We aimed to investigate whether sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a decreased risk of gastrointestinal (GI) cancers in patients with type 2 diabetes (T2D) compared to other glucose lowering medications (oGLMs).. Methods: This active-comparator, new-user cohort study used the nationwide National Health Insurance Service database of the Republic of Korea from September 2014 to June 2020.. From 79,423 new users of SGLT2is and 294,707 new users of oGLMs, we used a propensity score to match 59,954 from each of these two treatment groups. Article Title: Epidemiology of Carpal Tunnel Syndrome and Trigger Finger in South Korea: A Nationwide Population-Based Study Article Snippet: All statistical analyses were performed using the SAS |